Akebia Therapeutics (NASDAQ:AKBA) has grabbed attention from the analysts, when it saw a value increase of 3.31% or 0.23 points in the last trading session to close at $7.17. A total of 1.1 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 517.53 Million shares, while its relative volume stands at 2.16. Akebia Therapeutics (NASDAQ:AKBA) has a market cap of $409.12 Million and the number of outstanding shares have been calculated 57.06 Million.
Shares of Akebia Therapeutics (NASDAQ:AKBA) currently have an Average Brokerage Recommendation of 1.67, number of Recs in ABR is 6 while industry rank of the company by ABR is out of 257. Out of the analyst recommendations 1 rate Akebia Therapeutics (NASDAQ:AKBA) stock a Buy, 5 rate the stock Outperform, 2 rate Hold, 0 rate Underperform and 0 recommend a Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $18.63 on the stock, this valuation is based on 8 number of opinions. The most optimistic analyst sees the stock reaching $30 while the most conventional has $9 target price.
Akebia Therapeutics (NASDAQ:AKBA) as of recent trade, has shown weekly downbeat performance of -4.27% which was maintained at -13.93% in 1-month period. During the past three months the stock slid -12.56%, bringing six months performance to -30.79%. Yearly performance of the stock shows a bearish trend of -54.59% while year-to-date (YTD) performance reflected -51.78% negative outlook.
While taking a glance at financials, we can look at a number of key indicators. Akebia Therapeutics (NASDAQ:AKBA) has trailing twelve month Return on Assets of -17.5%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -45.4% and a Return on Investment of -65.2%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Akebia Therapeutics (NASDAQ:AKBA) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at -32.6% whereas its trailing twelve month net profit margin spots at -30.3%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Akebia Therapeutics (NASDAQ:AKBA)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 1.1.
The company’s quick ratio for most recent quarter is 2.2 along with current ratio for most recent quarter of 2.2. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.